The news is directly related to Rani Therapeutics Hldgs and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the stock's value in the short term. However, the impact may be neutral as the 'Buy' rating suggests the stock is still a good investment.